Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials by Feller, Martin et al.
Antibiotic Treatment for Crohn’s Disease • CID 2010:50 (15 February) • 473
M A J O R A R T I C L E
Long-Term Antibiotic Treatment for Crohn’s Disease:
Systematic Review and Meta-Analysis of Placebo-
Controlled Trials
Martin Feller,1 Karin Huwiler,1 Alain Schoepfer,3,4 Aijing Shang,1 Hansjakob Furrer,2 and Matthias Egger1,5
Institutes of 1Social and Preventive Medicine and 2Infectious Diseases, University of Bern, and 3Department of Visceral Surgery and Medicine,
Inselspital, Bern University Hospital, Bern, Switzerland; 4Farncombe Family Institute of Digestive Health Research, McMaster University, Hamilton,
Ontario, Canada; and 5Department of Social Medicine, University of Bristol, Bristol, England
Background. We investigated the effectiveness of long-term antibiotic treatment in patients with Crohn’s
disease.
Methods. We performed a systematic review and meta-analysis of randomized clinical trials. Data sources were
Medline (from 1966 through June 2009), EMBASE (from 1980 through June 2009), Cochrane Central Register
of Controlled Trials (issue 3, 2009), and references from relevant publications. Trials that compared antibiotic
therapy during at least 3 months with placebo were included. Outcomes were remission in patients with active
disease and relapse in patients with inactive disease. Results from intention-to-treat analyses were combined in a
random-effects meta-analysis, stratified by class of drug. Odds ratios (ORs) 11 indicate superiority of antibacterial
treatment over placebo. Numbers needed to treat for 1 year to keep 1 additional patient in remission were calculated.
Results. Sixteen trials that examined 13 treatment regimens in 865 patients were included in the meta-analysis.
The median duration of treatment was 6 months (range, 3–24 months). Three trials of nitroimidazoles showed
benefit, with a combined OR of 3.54 (95% confidence interval [CI], 1.94–6.47). Similarly, the combined OR from
4 trials of clofazimine was 2.86 (95% CI, 1.67–4.88). For patients with active disease, the number needed to treat
was 3.4 (95% CI, 2.3–7.0) for nitroimidazoles and 4.2 (95% CI, 2.7–9.3) for clofazimine. The corresponding
numbers needed to treat for inactive disease were 6.1 (95% CI, 5.0–9.7) and 6.9 (95% CI, 5.4–12.0). No benefit
was evident for classic drugs against tuberculosis (3 trials; OR, 0.58; 95% CI, 0.29–1.18). Results for clarithromycin
were heterogeneous ( ; ) and not combined in the meta-analysis.2I p 77% Pp .005
Conclusions. Long-term treatment with nitroimidazoles or clofazimine appears to be effective in patients with
Crohn’s disease.
The defect underlying the pathogenesis of Crohn’s dis-
ease may be impaired innate immunity [1]. This hy-
pothesis is supported by the association of Crohn’s dis-
ease with variants of the CARD15/NOD2 gene [2–4].
Defective CARD15/NOD2 variants lead to decreased
macrophage activation in response to intracellular li-
popolysaccharides, which in turn could result in the
activation of other inflammatory pathways [2]. Inde-
pendent of the CARD15/NOD2 genotype, impaired in-
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nate immunity could lead to intestinal content breach-
ing the mucosal barrier of the bowel wall [5]. In the
absence of adequate numbers of functional neutrophils
to clear bacteria, these may be ingested by macrophages
to form the granulomata and chronic inflammation
typical of Crohn’s disease. Consequently, there is re-
newed interest in the microbes associated with Crohn’s
disease. Several bacteria have been implicated, includ-
ing, for example, Listeria monocytogenes, Yersinia en-
terocolitica, Mycobacterium avium subspecies paratu-
berculosis, or Escherichia coli [6–12].
If microbes are involved in the development and
persistence of inflammation in Crohn’s disease, then
treatment with antibacterial drugs should be beneficial.
However, at present, guidelines and opinion leaders
consider antibiotics appropriate only in the manage-
ment of some complications, such as sepsis, symptoms
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attributable to bacterial overgrowth, or perianal disease [13–
15]. Despite this, there have been a number of trials of long-
term antibacterial therapy that examined their effect on the
course of Crohn’s disease independent of such complications.
With the exception of a meta-analysis of trials of antimyco-
bacterial therapy [16], these trials have never been compre-
hensively reviewed. We therefore performed a systematic review
and meta-analysis of randomized, placebo-controlled clinical
trials to assess the effectiveness of long-term antibiotic treat-
ment in patients with Crohn’s disease.
METHODS
Literature search. We searched the Medline database from
1966 through June 2009 using keywords that denote Crohn’s
disease or inflammatory bowel diseases and antibacterial and
antimycobacterial drugs. The results from this search were com-
bined with the search strategy for controlled clinical trials of
the Cochrane Collaboration [17]. Similar searches were per-
formed in EMBASE for the period from 1980 through June
2009 and the Cochrane Central Register of Controlled Trials
(issue 3, 2009). No language restrictions were applied. Finally,
we checked references from relevant publications and review
articles.
Eligibility criteria. Clinical trials were included if they used
random allocation of patients to treatment groups and com-
pared antibacterial agents, including combination regimens,
with placebo in patients with Crohn’s disease. The duration of
treatment had to be at least 3 months to exclude studies of
short-term antibiotic therapy in the management of bacterial
complications during flare-ups of the disease. Studies admin-
istering concomitant steroids or other drugs were included if
regimens were identical in the 2 groups. We excluded trials of
patients with exclusive perianal Crohn’s disease or trials that
reported insufficient data to calculate odds ratios (ORs). Two
reviewers (M.F. and K.H.) independently assessed the eligibility
of publications. Discrepancies were resolved by consensus in
consultation with a third reviewer (M.E.).
Data extraction, outcomes, and definitions. Two observers
(M.F. and K.H.) independently extracted data using a stan-
dardized data extraction sheet, with differences resolved by con-
sensus. We extracted bibliographic, sociodemographic, and
clinical data, aspects of study quality, and results. Remission in
patients with active disease and relapse in patients with inactive
disease were the outcomes of interest. There was no single,
standardized definition of outcomes, which may be explained
by the fact that most trials were performed before the publi-
cation of the consensus statement on definitions of remission
or relapse [18]. We used the definitions reported in the pub-
lications, including, for example, the Crohn’s Disease Activity
Index [19]. If a study presented outcome data at 11 point, we
analyzed the data from the latest assessment during treatment.
Ethambutol, isoniazid, and rifamycins (eg, rifampicin and
rifabutin) were considered to be classic drugs against infection
with Mycobacterium tuberculosis, and trials of 1 or several an-
tituberculosis drugs were combined in the meta-analysis. Sim-
ilarly, trials of drugs from other drug classes, including nitroim-
idazoles (metronidazole and ornidazole), macrolides (clarithro-
mycin), and riminophenazines (clofazimine), were also ana-
lyzed together.
Statistical analysis. Data were analyzed according to the
intention-to-treat principle. Patients lost to follow-up or ex-
cluded from the study for other reasons were considered treat-
ment failures (ie, not in remission or with relapse). Study results
are presented as ORs with 95% confidence intervals (CIs). For
studies with continuous outcome measures, results were con-
verted to ORs using the method described by Hasselblad and
Hedges [20]. The method is based on the fact that, when as-
suming logistic distributions and equal variances in the 2 treat-
ment groups, the log OR corresponds to a constant multiplied
by the standardized difference between means. We coded out-
comes so that ORs 11 indicated superiority of antibacterial
treatments over placebo. Results were combined in a random-
effects meta-analysis, stratified by drug class, if the degree of
between-trial heterogeneity was moderate or low. We assessed
between-trial heterogeneity by calculating the I2 statistic [21].
Low, moderate, and high levels of heterogeneity correspond to
I2 values of 25%, 50%, and 75%, respectively. Numbers needed
to treat to keep 1 additional patient in remission were based
on the combined ORs and typical proportions of patients in
remission after 1 year in the placebo groups, with 95% CIs
calculated as suggested by Altman [22]. Publication bias was
examined by inspection of funnel plots. All analyses were per-
formed with Stata statistical software, version 10.0 (StataCorp).
RESULTS
The process of identifying eligible studies is summarized in
Figure 1. Forty-three potentially eligible publications were as-
sessed in detail, and 16 trials [23–38] met the eligibility criteria
(Table 1). A list of the 27 excluded trials with reasons for
exclusion is available from the authors on request. Outcome
measures were continuous in 4 trials [25, 27, 37, 38] and cat-
egorical in the others. Two trials [32, 37] compared 2 dosages
of the antibacterial agent to placebo: we included the com-
parison with the higher dosage.
Study characteristics, definitions, and outcomes. Table 1
gives the characteristics of the 16 included trials. The median
number of patients included in the trials was 48 (range, 14–
213), and the median year of publication was 1995 (range,
1982–2008). Fifteen trials were parallel-group trials, and 1 trial
[36] was a crossover study. The quality of reporting of study
methods tended to be low. Only 4 studies [25, 30, 31, 38]
described adequate methods of allocation concealment; in the
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Figure 1. Identification of 16 eligible randomized, placebo-controlled
clinical trials comparing antibacterial therapy of at least 3 months duration
with placebo in patients with Crohn’s disease.
remaining studies, this was unclear. Two studies reported
blinded outcome assessment [33, 38].
Eleven studies included only patients with active disease, 3
studies examined patients with inactive disease, and 1 study
included both types of patients; in 1 study, it was unclear
whether patients had active or inactive disease. In most studies
the diagnostic criteria for Crohn’s disease were described as
standard clinical findings, with typical radiologic, endoscopic,
or histologic lesions. Four studies did not report diagnostic
criteria [28, 29, 33, 35]. Remission or recurrence of symptoms
was the main outcome in all studies. In 15 studies, a disease
activity index was used to assess outcomes (the Crohn’s Disease
Activity Index [19] in 11 studies), and in 1 study recurrence
of lesions was the main outcome [33].
Treatment regimens. Thirteen different treatment regi-
mens were examined. These regimens ranged from single drugs
to combination regimens of up to 4 different drugs. The median
duration of the active study period was 6 months (range, 3–
24 months). Classic drugs against tuberculosis were used in 3
studies [25, 36, 38], nitroimidazoles were used in another 3
studies [33, 34, 37], clarithromycin was used in 4 studies [27,
28, 30, 35], and clofazimine was also used in 4 studies [23, 29,
31, 35] (Table 1). Three studies included a course of steroids,
with the same decreasing doses over time in the 2 arms [23,
31, 35]. Seven studies allowed steroids as clinically indicated,
and 4 studies explicitly excluded the use of steroids during the
study period (Table 1).
Meta-analyses. The forest plot of the meta-analysis strat-
ified by drug class is shown in Figure 2. The combined OR
from the 3 trials [25, 36, 38], involving 107 patients, of classic
antituberculosis drugs was 0.58 (95% CI, 0.29–1.18), indicating
no benefit, with little between-trial heterogeneity ( ).2I p 0%
In contrast, the 3 trials [33, 34, 37] of nitroimidazoles, involving
206 patients, showed benefit: the combined OR was 3.54 (95%
CI, 1.94–6.47), again with little heterogeneity ( ). The2I p 0%
results from the 4 studies [27, 28, 30, 35] of clarithromycin
only or clarithromycin in combination, involving 287 patients,
were highly heterogeneous ( ; ) and therefore2I p 77% Pp .005
not combined in the meta-analysis. The trials of clofazimine
[23, 29, 31, 35], involving 322 patients, were homogenous
( ), with a combined OR of 2.86 (95% CI, 1.67–4.88).2I p 0%
A trial of 6 months of ciprofloxacin [24] also showed benefit,
with an OR of 11.3, but wide CIs (95% CI, 2.60–48.8). There
was little evidence of an effect in a trial of sulfadoxine combined
with pyrimethamine [26] or a trial of rifaximin [32]. The funnel
plot of the 16 studies included in the meta-analysis was sym-
metrical (Figure 3).
On the basis of the placebo groups of included studies [23,
31, 33–35] and 1 additional large study [39], we assumed that,
after 1 year, 25% of control patients with active disease and
75% of control patients with inactive disease will be in remis-
sion after 1 year. For patients with active disease, the estimated
number needed to treat to keep 1 additional patient in remis-
sion was 3.4 (95% CI, 2.3–7.0) for nitroimidazoles and 4.2
(95% CI, 2.7–9.3) for clofazimine. The corresponding figures
for inactive disease were 6.1 (95% CI, 5.0–9.7) and 6.9 (95%
CI, 5.4–12.0).
DISCUSSION
This systematic review and meta-analysis examined whether
antibacterial treatment for 3 months was efficacious in pa-
tients with Crohn’s disease. A substantial benefit was evident
for nitroimidazoles and clofazimine based on several trials and
for ciprofloxacin based on a single trial. Conversely, we found
little evidence of a benefit for clarithromycin or the classic
tuberculosis drugs.
Our review has several limitations. The number of trials
meta-analyzed in each class of drug was small (3 or 4), and
the trials also tended to be small, typically including ∼50 pa-
tients with Crohn’s disease. The methodologic quality of many
trials was uncertain because of incomplete reporting of study
procedures. Smaller trials tend to be of lower methodologic
quality and to show larger treatment effects [40], which would
be expected to be reflected in an asymmetrical funnel plot [41].
The funnel plot was, however, symmetrical, and results of trials
of nitroimidazoles and clofazimine were homogenous. The lat-
ter trials included the large Australian trial involving 1200 pa-
tients [23, 29, 31, 35]. Publication bias could also have distort-
ed our results, but again this should have been reflected in
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Figure 2. Meta-analysis of 16 randomized, placebo-controlled trials of antibacterial therapy for at least 3 months duration involving patients with
Crohn’s disease, stratified by drug classes. An odds ratio 11 indicates superiority of antibacterial treatment over placebo. The study from Selby et al
[35] appears twice, once in the clarithromycin group and once in the clofazimine group. CI, confidence interval.
an asymmetrical funnel plot. Finally, studies will have includ-
ed the 10%–15% of patients for whom the distinction be-
tween Crohn’s disease and ulcerative colitis cannot be made
with certainty (inflammatory bowel disease, type unclassified),
and this might have attenuated treatment effects [42].
Since the first description of the similarities between Crohn’s
disease and Johne disease in cattle in 1913 [43], it has been
suspected that M. avium subspecies paratuberculosis, which
causes Johne disease, might also be a cause of Crohn’s disease
[9, 44]. We found that both classic drugs against M. tuberculosis
and clarithromycin did not appear to be efficacious. Some have
argued that effective regimens should consist of at least 2 dif-
ferent drugs, include a macrolide and rifamycin, and be ad-
ministered for at least 6 months in a dosage similar to that
used in the treatment of M. avium complex infections [45–48].
No randomized trials of such regimens are available at present.
Interestingly, clofazimine was synthesized in the 1950s as a drug
against tuberculosis. Granted orphan drug status in 1986, it is
an important component of the treatment of leprosy and is
also used for multidrug-resistant tuberculosis and M. avium
complex infections in patients infected with human immu-
nodeficiency virus [49]. Our meta-analysis showed a beneficial
effect of clofazimine in Crohn’s disease and found that results
of the Australian trial [35] were compatible with those of the
previous studies [23, 29, 31]. Of note, the published results of
the Australian trial were not based on an intention-to-treat
analysis and may have underestimated the beneficial effects of
the drug [50].
The earlier trials of clofazimine [23, 29, 31] showed benefits
in the absence of coadministered macrolides or rifamycins. The
antibiotic activity of clofazimine includes some gram-positive
bacteria, whereas gram-negative bacteria are uniformly resistant
to clofazimine [51, 52]. Clofazimine also has immunomodu-
latory effects that have been attributed to the stimulation of
the production of prostaglandin E2 [49]. It is unclear to what
extent the beneficial effect of clofazimine might be explained
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Figure 3. Funnel plot of 16 randomized, placebo-controlled trials using
treatment regimens with antibacterial agents for at least 3 months in
patients with Crohn’s disease. Asymmetry of the plot is an indication of
publication bias. SE, standard error.
by the immunomodulatory effects of the drug. Similarly, ni-
troimidazoles are widely used to treat infections by anaerobic
bacteria, whereas facultative anaerobic and aerobic bacteria are
uniformly resistant against nitroimidazoles [53, 54]. Anaerobic
bacteria have, however, not been implicated in the pathogenesis
of Crohn’s disease [7]. Immunomodulatory activities, rather
than the anti-infectious effects of nitroimidazoles, might thus
also explain the beneficial effects observed in Crohn’s disease
[55, 56].
The current focus in the therapy of Crohn’s disease is on
tumor necrosis factor a blocking agents: a recent review of the
medical management of Crohn’s disease discussed this in detail
but spent only 2 sentences on antibiotic therapy [15]. Never-
theless, long-term therapy with nitroimidazoles (metronidazole
and ornidazole, in particular) is routinely used in some cen-
ters, outside the fairly narrow indications suggested by cur-
rent guidelines [14, 15], but its efficacy has never been system-
atically assessed. Our review indicates that the benefit of some
antibiotic regimens given for 3 months may be comparable
to what is achieved with the anti–tumor necrosis factor a agents
[57], with a potentially more favorable adverse effect profile
and lower costs.
We believe that further research is justified to better define
the role of antibacterial agents and combination regimens in
Crohn’s disease. Future studies should focus on clofazimine,
alone or in combination with a macrolide and a rifamycin, as
well as in combination with a nitroimidazole, and perhaps
ciprofloxacin. Both pragmatic trials comparing different treat-
ment strategies and smaller studies aiming to elucidate mech-
anisms of action are required. The potential role of different
bacteria should be examined in such trials and interactions
between drugs and potential adverse effects of long-term an-
tibiotic treatment assessed [58]. Better characterization of pa-
tients, for example, by using the recently developed Montreal
classification of inflammatory bowel disease [42], should also
be considered when planning future studies. Finally, the ac-
cumulating evidence should be systematically reviewed in reg-
ular intervals to inform up-to-date guidelines of the treatment
of Crohn’s disease.
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